Are breast cancer molecular classes predictive of survival in patients with long follow-up?

Disease Markers

Volumn 35, Issue 6, 2013, Pages 595-605

  Pracella, Danae ^a   Bonin, Serena ^a   Barbazza, Renzo ^a   Sapino, Anna ^b   Castellano, Isabella ^b   Sulfaro, Sandro ^c   Stanta, Giorgio ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c S MARIA DEGLI ANGELI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROGESTERONE RECEPTOR; VIMENTIN;

ADULT; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; DISEASE CLASSIFICATION; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR VOLUME;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL PROLIFERATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; VIMENTIN;

EID: 84888867993     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2013/347073     Document Type: Article

References (36)

1. Colombo P. E., Milanezi F., Weigelt B., Reis-Filho J. S., Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Research 2011 13 212 10.1186/bcr2890
2. Perou C. M., Sørile T., Eisen M. B., Van De Rijn M., Jeffrey S. S., Ress C. A., Pollack J. R., Ross D. T., Johnsen H., Akslen L. A., Fluge Ø., Pergammenschlkov A., Williams C., Zhu S. X., Lønning P. E., Børresen-Dale A.-L., Brown P. O., Botstein D., Molecular portraits of human breast tumours. Nature 2000 406 6797 747 752 2-s2.0-0034680102 10.1038/35021093
3. Sørlie T., Perou C. M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M. B., Van De Rijn M., Jeffrey S. S., Thorsen T., Quist H., Matese J. C., Brown P. O., Botstein D., Lønning P. E., Børresen-Dale A.-L., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America 2001 98 19 10869 10874 2-s2.0-0035845511 10.1073/pnas.191367098
4. Weigelt B., Baehner F. L., Reis-Filho J. S., The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. Journal of Pathology 2010 220 2 263 280 2-s2.0-73949136029 10.1002/path.2648
5. Cheang M. C. U., Chia S. K., Voduc D., Gao D., Leung S., Snider J., Watson M., Davies S., Bernard P. S., Parker J. S., Perou C. M., Ellis M. J., Nielsen T. O., Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. Journal of the National Cancer Institute 2009 101 10 736 750 2-s2.0-66849140730 10.1093/jnci/djp082
6. Tang P., Skinner K. A., Hicks D. G., Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready? Diagnostic Molecular Pathology 2009 18 3 125 132 2-s2.0-69749116768 10.1097/PDM.0b013e31818d107b
7. Goldhirsch A., Wood W. C., Coates A. S., Gelber R. D., Thürlimann B., Senn H.-J., Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Annals of Oncology 2011 22 8 1736 1747 2-s2.0-79960980007 10.1093/annonc/mdr304
8. Gruver A. M., Portier B. P., Tubbs R. R., Molecular pathology of breast cancer the journey from traditional practice toward embracing the complexity of a molecular classification. Archives of Pathology and Laboratory Medicine 2011 135 5 544 557 2-s2.0-79956372637
9. Guiu S., Michiels S., Andre F., Cortes J., Denkert C., Di Leo A., Hennessy B. T., Sorlie T., Sotiriou C., Turner N., Van de Vijver M., Viale G., Loi S., Reis-Filho J. S., Molecular subclasses of breast cancer: how do we define them? The IMPAKT, 2012 Working Group Statement. Annals of Oncology 2012 23 2997 3006
10. Müller B. M., Kronenwett R., Hennig G., Euting H., Weber K., Bohmann K., Weichert W., Altmann G., Roth C., Winzer K.-J., Kristiansen G., Petry C., Dietel M., Denkert C., Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue-a new option for predictive biomarker assessment in breast cancer. Diagnostic Molecular Pathology 2011 20 1 1 10 2-s2.0-79952167236 10.1097/PDM.0b013e3181e3630c
11. Park S., Koo J. S., Kim M. S., Park H. S., Lee J. S., Lee J. S., Kim S. I., Park B.-W., Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast 2012 21 1 50 57 2-s2.0-84856358910 10.1016/j.breast.2011.07.008
12. Rakha E. A., Reis-Filho J. S., Ellis I. O., Basal-like breast cancer: a critical review. Journal of Clinical Oncology 2008 26 15 2568 2581 2-s2.0-45149094267 10.1200/JCO.2007.13.1748
13. Shao M. M., Chan S. K., Yu A. M., Lam C. C., Tsang J. Y., Lui P. C., Law B. K., Tan P. H., Tse G. M., Keratin expression in breast cancers. Virchows Archiv 2012 461 3 313 322 10.1007/s00428-012-1289-9
14. Geyer F. C., Rodrigues D. N., Weigelt B., Reis-Filho J. S., Molecular classification of estrogen receptor-positive/luminal breast cancers. Advances in Anatomic Pathology 2012 19 1 39 53 2-s2.0-83755174643 10.1097/PAP. 0b013e31823fafa0
15. Rakha E. A., Ellis I. O., Modern classification of breast cancer: should we stick with morphology or convert to molecular profile characteristics. Advances in Anatomic Pathology 2011 18 4 255 267 2-s2.0-79959254818 10.1097/PAP.0b013e318220f5d1
16. Ellis I. O., Schnitt S. J., Sastre-Garau X., Bussolati G., Tavassoli F. A., Eusebi V., Peterse J. L., Mukai K., Tabar L., Jacquemier J., Cornelisse C. J., Sasco A. J., Kaaks R., Pisani P., Goldgar D. E., Devilee P., Cleton-Jansen M. J., Borresen-Dale A. L., van't Veer L., World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Breast and Female Genital Organs 2003 Lyon, France IARC Press. Edited by Tavassoli F. A., Devilee P
17. Elston C. W., Ellis I. O., Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991 19 5 403 410 2-s2.0-0026072872
18. Edge S. B., Byrd D. R., Compton C. C., Fritz A. G., Greene F. L., Trotti A., AJCC Cancer Staging Manual 2010 7th Edition
19. Faoro V., Sapino A., Stanta G., Tissue Microarray. Guidelines For Molecular Analysis in Archive Tissues 2011 Berlin, Germany Springer 23 26
20. Goldstein N. S., Hewitt S. M., Taylor C. R., Yaziji H., Hicks D. G., Ridolfi R. L., Dabbs D. J., Martin A. W., Badve S., Hessling J., Recommendations for improved standardization of immunohistochemistry. Applied Immunohistochemistry and Molecular Morphology 2007 15 2 124 133 2-s2.0-34249696011 10.1097/PAI.0b013e31804c7283
21. Ramieri M. T., Murari R., Botti C., Pica E., Zotti G., Alo P. L., Detection of HER2 amplification using the SISH technique in breast, colon, prostate, lung and ovarian carcinoma. Anticancer Research 2010 30 4 1287 1292 2-s2.0-77953765547
22. Castellano I., Allia E., Accortanzo V., Vandone A. M., Chiusa L., Arisio R., Durando A., Donadio M., Bussolati G., Coates A. S., Viale G., Sapino A., Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Research and Treatment 2010 124 3 607 617 2-s2.0-78249249431 10.1007/s10549-010-0761-y
23. Li X.-R., Liu M., Zhang Y.-J., Wang J.-D., Zheng Y.-Q., Li J., Ma B., Song X., Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer. Medical Oncology 2011 28 1 S31 S38 2-s2.0-84655170220 10.1007/s12032-010-9676-z
24. Hammond M. E. H., Hayes D. F., Wolff A. C., Mangu P. B., Temin S., American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Journal of Oncology Practice 2010 6 4 195 197 2-s2.0-78149287242 10.1200/JOP.777003
25. Kusinska R. U., Kordek R., Pluciennik E., Bednarek A. K., Piekarski J. H., Potemski P., Does vimentin help to delineate the so-called 'basal type breast cancer'? Journal of Experimental and Clinical Cancer Research 2009 28 1, article 118 2-s2.0-69949132602 10.1186/1756-9966-28-118
26. Wolff A. C., Hammond M. E. H., Schwartz J. N., Hagerty K. L., Allred D. C., Cote R. J., Dowsett M., Fitzgibbons P. L., Hanna W. M., Langer A., McShane L. M., Paik S., Pegram M. D., Perez E. A., Press M. F., Rhodes A., Sturgeon C., Taube S. E., Tubbs R., Vance G. H., Van De Vijver M., Wheeler T. M., Hayes D. F., American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Journal of Clinical Oncology 2007 25 1 118 145 2-s2.0-33847147313 10.1200/JCO.2006.09.2775
27. Dawood S., Hu R., Homes M. D., Collins L. C., Schnitt S. J., Connolly J., Colditz G. A., Tamimi R. M., Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Research and Treatment 2011 126 1 185 192 2-s2.0-79151476372 10.1007/s10549-010-1113-7
28. Rakha E. A., Reis-Filho J. S., Ellis I. O., Combinatorial biomarker expression in breast cancer. Breast Cancer Research and Treatment 2010 120 2 293 308 2-s2.0-77950691476 10.1007/s10549-010-0746-x
29. Valentin M. D., da Silva S. D., Privat M., Alaoui-Jamali M., Bignon Y.-J., Molecular insights on basal-like breast cancer. Breast Cancer Research and Treatment 2012 1 10 2-s2.0-84855474195 10.1007/s10549-011-1934-z
30. Wiechmann L., Sampson M., Stempel M., Jacks L. M., Patil S. M., King T., Morrow M., Presenting features of breast cancer differ by molecular subtype. Annals of Surgical Oncology 2009 16 10 2705 2710 2-s2.0-73349089659 10.1245/s10434-009-0606-2
31. Weigelt B., Geyer F. C., Reis-Filho J. S., Histological types of breast cancer: How special are they? Molecular Oncology 2010 4 3 192 208 2-s2.0-77953873673 10.1016/j.molonc.2010.04.004
32. Livasy C. A., Karaca G., Nanda R., Tretiakova M. S., Olopade O. I., Moore D. T., Perou C. M., Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Modern Pathology 2006 19 2 264 271 2-s2.0-30944450821 10.1038/modpathol.3800528
33. García Fernández A., Giménez N., Fraile M., González S., Chabrera C., Torras M., González C., Salas A., Barco I., Cirera L., Cambra M. J., Veloso E., Pessarrodona A., Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. A single institution survey spanning 1998 to 2010. Breast 2012 21 366 373 2-s2.0-84859337168 10.1016/j.breast.2012.03.004
34. Crabb S. J., Cheang M. C. U., Leung S., Immonen T., Nielsen T. O., Huntsman D. D., Bajdik C. D., Chia S. K., Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clinical Breast Cancer 2008 8 3 249 256 2-s2.0-46949096398 10.3816/CBC.2008.n.028
35. Heatley M., Whiteside C., Maxwell P., Toner P., Vimentin expression in benign and malignant breast epithelium. Journal of Clinical Pathology 1993 46 5 441 445 2-s2.0-0027174258
36. Tausch C., Taucher S., Dubsky P., Seifert M., Reitsamer R., Kwasny W., Jakesz R., Fitzal F., Filipcic L., Fridrik M., Greil R., Gnant M., Prognostic value of number of removed lymph nodes, number of involved lymph nodes, and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG). Annals of Surgical Oncology 2012 19 1808 1817 2-s2.0-84455169004 10.1245/s10434-011-2189-y